Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin

Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehtisalo, Minna, Keskitalo, Jenni E., Tornio, Aleksi, Lapatto‐Reiniluoto, Outi, Deng, Feng, Jaatinen, Taina, Viinamäki, Jenni, Neuvonen, Mikko, Backman, Janne T., Niemi, Mikko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719384/
https://www.ncbi.nlm.nih.gov/pubmed/32453913
http://dx.doi.org/10.1111/cts.12809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719384/
https://www.ncbi.nlm.nih.gov/pubmed/32453913
http://dx.doi.org/10.1111/cts.12809

Ejemplares similares